Evidence Intelligence™
- ImpactScore™
- 76
- Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Liraglutide improves glycaemic control in adults with T2D
Última actualización 5 de julio de 2026
Key finding
Overall change in HbA1c was -1.02% for liraglutide compared to -0.28% for placebo.
The study evaluated the addition of liraglutide to SGLT2 inhibitors and metformin in adults with type 2 diabetes, showing significant improvements in glycaemic control.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
The study evaluated the addition of liraglutide to SGLT2 inhibitors and metformin in adults with type 2 diabetes, showing significant improvements in glycaemic control.
Clinical relevance
Improving glycaemic control is crucial for managing type 2 diabetes and reducing the risk of complications. The findings suggest that liraglutide can enhance treatment efficacy when combined with standard medications, potentially leading to better health outcomes for patients.
Keep in mind
Non-randomized design may introduce bias. Sample size and diversity not specified. Some outcomes showed no significant differences.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Lawrence B, Udi F, Margit SK, Ofri M, Chethana R, Rosangela R. Liraglutide Added to SGLT2 Inhibitors and Metformin Improves Glycaemic Control in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2021;23(10):2234-2241. doi:10.1111/dom.14464
Efectos Principales
Liraglutide reduced HbA1c by -1.02% compared to placebo (p = 0.001).
Body weight decreased by -2.92 kg with liraglutide versus -2.06 kg for placebo (p = 0.06).
Waist circumference decreased by -4.26 cm for liraglutide compared to -2.24 cm for placebo (p = 0.05).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide and Body weight, Emergency cesarean section rate, HbA1c, and 3 more.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
- Body weight
- Emergency cesarean section rate
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
352
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Seguir evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Body Composition
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Emergency cesarean section rate
Liraglutide → Emergency cesarean section rate
Liraglutide → Emergency cesarean section rate
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerType 2 diabetes incidence
Liraglutide → Type 2 diabetes incidence
Liraglutide → Type 2 diabetes incidence
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerUrinary tract infection rate
Liraglutide → Urinary tract infection rate
Liraglutide → Urinary tract infection rate
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- ImpactScore™
- 75
- Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- Liraglutide significantly lowered HbA1c by 1.02%.
- Body weight reduction was greater with liraglutide (-2.92 kg).
- Waist circumference decreased more with liraglutide (-4.26 cm).
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Individuals currently on SGLT2 inhibitors and metformin.
Tener en Cuenta
- Results may not generalize to all populations.
- Further studies needed to confirm findings.
- Effectiveness of liraglutide may vary among individuals.
Entre Líneas
- Non-randomized design may introduce bias.
- Sample size and diversity not specified.
- Some outcomes showed no significant differences.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceGLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- ImpactScore™
- 76
- Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
View evidenceMedications
Detailed evidenceGLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- ImpactScore™
- 100
- Very Positive
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
4 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
4 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
2 studies
outcome_hubMeasures HbA1c as a key outcome.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Liraglutide and Body weight
Intervention: LiraglutideOutcome: Body weight
4 results
All studies on Liraglutide and HbA1c
Intervention: LiraglutideOutcome: HbA1c
2 results
All studies on Liraglutide
Intervention: Liraglutide
4 results
All studies measuring Body weight
Outcome: Body weight
4 results
All studies measuring HbA1c
Outcome: HbA1c
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve body composition?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Waist circumference
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve diabetes incidence and prevention?
Moderate Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Diabetes Incidence and Prevention.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Type 2 diabetes incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetesLiraglutide 3 mg pathway improves weight loss.Mediterranean ketogenic eating matched VLCKD for weight loss over 3 months
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.